CY2290B1 - Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia - Google Patents

Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia

Info

Publication number
CY2290B1
CY2290B1 CY0200048A CY0200048A CY2290B1 CY 2290 B1 CY2290 B1 CY 2290B1 CY 0200048 A CY0200048 A CY 0200048A CY 0200048 A CY0200048 A CY 0200048A CY 2290 B1 CY2290 B1 CY 2290B1
Authority
CY
Cyprus
Prior art keywords
xerostomia
salivary gland
spirooxathiolane
alkyl
treatment
Prior art date
Application number
CY0200048A
Other languages
English (en)
Inventor
Harumi Handa
Yasuyoshi Takeshita
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of CY2290B1 publication Critical patent/CY2290B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
CY0200048A 1994-06-27 2002-07-31 Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia CY2290B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6168982A JP2852608B2 (ja) 1994-06-27 1994-06-27 口腔乾燥症治療剤

Publications (1)

Publication Number Publication Date
CY2290B1 true CY2290B1 (en) 2003-07-04

Family

ID=15878165

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200048A CY2290B1 (en) 1994-06-27 2002-07-31 Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia

Country Status (15)

Country Link
US (1) US5580880A (ja)
EP (1) EP0689836B1 (ja)
JP (1) JP2852608B2 (ja)
KR (1) KR100322042B1 (ja)
AT (1) ATE205085T1 (ja)
AU (1) AU707236B2 (ja)
CA (1) CA2152420A1 (ja)
CY (1) CY2290B1 (ja)
DE (1) DE69522511T2 (ja)
DK (1) DK0689836T3 (ja)
ES (1) ES2163474T3 (ja)
IL (1) IL114256A (ja)
NO (1) NO309454B1 (ja)
TW (1) TW401298B (ja)
ZA (1) ZA955317B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP4909809B2 (ja) * 1999-03-24 2012-04-04 生化学工業株式会社 人工唾液
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8450487B2 (en) 2010-06-08 2013-05-28 Apicore, Llc Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
WO2017094910A1 (ja) 2015-12-04 2017-06-08 三栄源エフ・エフ・アイ株式会社 酵素処理イソクエルシトリンの利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US5078129A (en) * 1987-05-01 1992-01-07 Research Foundation Of State University Of New York Device for stimulating salivation
IL87234A (en) 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US4917674A (en) * 1988-04-04 1990-04-17 Molinoff Henry C Mouth moisturizing device
US4906455A (en) * 1988-04-15 1990-03-06 Wm. Wrigley Jr. Company Method for treating xerostomia employing chewing gum containing relatively insoluble, hydrophobic, food-grade organic acid
US4983378A (en) * 1988-11-22 1991-01-08 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
JP3018494B2 (ja) * 1990-11-30 2000-03-13 ソニー株式会社 特殊効果装置
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤

Also Published As

Publication number Publication date
JPH0812575A (ja) 1996-01-16
JP2852608B2 (ja) 1999-02-03
KR960000222A (ko) 1996-01-25
NO309454B1 (no) 2001-02-05
IL114256A0 (en) 1995-10-31
ATE205085T1 (de) 2001-09-15
EP0689836A1 (en) 1996-01-03
NO952561L (no) 1995-12-28
DE69522511D1 (de) 2001-10-11
ZA955317B (en) 1996-02-02
TW401298B (en) 2000-08-11
AU2324595A (en) 1996-01-11
ES2163474T3 (es) 2002-02-01
IL114256A (en) 1999-05-09
DE69522511T2 (de) 2002-05-16
CA2152420A1 (en) 1995-12-28
AU707236B2 (en) 1999-07-08
NO952561D0 (no) 1995-06-26
KR100322042B1 (ko) 2002-11-04
DK0689836T3 (da) 2002-05-06
US5580880A (en) 1996-12-03
EP0689836B1 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
CY2290B1 (en) Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia
DE69019111D1 (de) Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion.
EE05530B1 (et) Gamma-aminov?ihappe derivaate sisaldavad tahked kompositsioonid ja nende saamise meetod
OA09334A (fr) "Dérivés d'acides aminés".
HUP0302962A2 (hu) Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
ATE81459T1 (de) Verwendung von salzen der n-acetylneuraminsaeure zur herstellung eines arzneimittels zum abschwellen der nasenschleimhaut.
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
IL106218A0 (en) Pharmaceutical composition for curing sjoegren syndrome disease
DE3873578T2 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE137969T1 (de) Benzimidazolverbindungen als antibiotika gegen campylobacter pylon
IL90552A0 (en) Condensed pyrazole 3-oxo-propanenitrile derivatives,their preparation and pharmaceutical compositions containing them
DE69030502D1 (de) Cephalosporinverbindungen und deren herstellung
ATE34662T1 (de) Derivate der benzoesaeure, herstellungsverfahren und anwendung in desinfizierenden und konservierenden arzneimitteln.
KR880007070A (ko) 백내장 치료용 약학 조성물
ATE40521T1 (de) Verwendung eines substanzgemisches fuer die herstellung eines mittels gegen buergers krankheit.
ATE252089T1 (de) Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln
ATE249442T1 (de) Polyhydroxyalkylpyrazine derivate, deren herstellung,diese enthaltende arzneimitteln
NZ509703A (en) Therapeutic agent comprising spirooxathiolane-quinuclidine for the treatment of dry mouth
FI791976A (fi) Nya n1-bensoyl-n2-fenyl-1,3-diaminopropan-2-oler och deras salter foerfarande foer framstaellning av dessa samt laekemedel innehaollande dessa foereningar
ES8300709A1 (es) Un metodo para la preparacion de derivados de pirazolidinona
DE3784883T2 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.
ATE6514T1 (de) Clavulansaeure-derivate, ihre herstellung und pharmazeutische zubereitungen.
TH35996A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับรักษาโรคผิวหนังอักเสบเนื่องจากไขมันมากผิดปกติ